Cargando…

External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis

BACKGROUND: Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). AIM: To independently evaluate the predictive performan...

Descripción completa

Detalles Bibliográficos
Autores principales: Gazda, Jakub, Janicko, Martin, Drazilova, Sylvia, Grgurevic, Ivica, Kanizaj, Tajana Filipec, Koller, Tomas, Bodorovska, Beatrica, Mijic, Maja, Mikolasevic, Ivana, Stromar, Ivana Knezevic, Kucinsky, Branislav, Gazda, Matej, Jarcuska, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245238/
https://www.ncbi.nlm.nih.gov/pubmed/34258254
http://dx.doi.org/10.1155/2021/9928065
Descripción
Sumario:BACKGROUND: Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). AIM: To independently evaluate the predictive performance of the URS model. METHODS: We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. RESULTS: One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. CONCLUSION: Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy.